The question of cannabis legality is closely linked to its potential medical applications. An interesting phenomenon can be observed in many countries and regions: While cannabis has already been approved for medical purposes in numerous U.S. states, the legal situation remains often contradictory in other areas. This discrepancy raises legitimate questions – if a substance is recognized for medical applications in over 38 states, should this not also influence the general legalization debate?
In Switzerland, the situation is nuanced: CBD-containing products with a THC content below 1% have been legally available since 2011 and are enjoying growing popularity. Scientific research into cannabinoids is progressing continuously, with studies examining various applications. Regardless of legal classification, a global trend is evident: the medical relevance of cannabinoids is being taken seriously in scientific and political discussions. This speaks for a factual, evidence-based approach to regulatory policy.
At hashhash, we offer high-quality, legally available CBD and cannabis products that comply with Swiss regulations. Our selection allows interested customers to explore the diversity of these plants – always in accordance with applicable laws.
